TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations
Brief Summary: The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
C: Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: clarithromycin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clarithromycin, Other: One-stage full-mouth ultrasonic debridement (FMUD) | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: One-stage full-mouth ultrasonic debridement (FMUD) | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): clarithromycin group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: OTHER; Name: One-stage full-mouth ultrasonic debridement (FMUD); Assigned to Arm(s): clarithromycin group, placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Patient Decision Aid Regarding Natural Health Products for Menopausal Symptoms:a Randomized Controlled Trial
Brief Summary: The aim of this study is to assess the impact of a patient decision aid regarding natural health products for menopausal symptoms on decisional conflict, knowledge and persistence for an option of women aged 45-64 years old. We are expecting a decrease in decisional conflict and an improvement on knowledge level. We are also expecting an intention to use the decision aid in the future and to discuss with the physician or pharmacist about the use, or the intention to use natural health products.


Options:
A: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
B: Intervention Type: BEHAVIORAL; Name: Decision aid; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
D: Intervention Type: OTHER; Name: informational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Newly Diagnosed Open Angle Glaucoma and Subjects Diagnosed With Ocular Hypertension
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with newly diagnosed open-angle glaucoma and subjects diagnosed with Ocular hypertension.


Options:
A: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy
B: Arm Label: A--iStent plus Cataract Surgery; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent plus Cataract Surgery | Arm Label: B--Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery only | Intervention Type: DEVICE; Name: iStent plus Cataract Surgery; Assigned to Arm(s): A--iStent plus Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract surgery only; Assigned to Arm(s): B--Cataract Surgery Only
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Glaucoma Surgery | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: cataract surgery only | Intervention Type: DEVICE; Name: Glaucoma Surgery; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: cataract surgery only; Assigned to Arm(s): 2
D: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)
Brief Summary: The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Options:
A: Arm Label: Lithium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium | Arm Label: Quetiapine; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium
B: Arm Label: Duloxetine Hydrochloride (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Arm Label: Duloxetine Hydrochloride (120 mg); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine hydrochloride, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine hydrochloride; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine Hydrochloride (120 mg), Duloxetine Hydrochloride (60 mg)
C: Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Brief Summary: This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.


Options:
A: Arm Label: Acustimulation; Type: EXPERIMENTAL; Interventions: Device: Transcutaneous electrical acupoint stimulation, Drug: Dexamethasone | Arm Label: Tropisetron; Type: ACTIVE_COMPARATOR; Interventions: Device: Sham transcutaneous electrical acupoint stimulation, Drug: Tropisetron, Drug: Dexamethasone | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcutaneous electrical acupoint stimulation, Drug: Dexamethasone | Intervention Type: DEVICE; Name: Transcutaneous electrical acupoint stimulation; Assigned to Arm(s): Acustimulation | Intervention Type: DEVICE; Name: Sham transcutaneous electrical acupoint stimulation; Assigned to Arm(s): Control, Tropisetron | Intervention Type: DRUG; Name: Tropisetron; Assigned to Arm(s): Tropisetron | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Acustimulation, Control, Tropisetron
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW679769 (casopitant) | Intervention Type: DRUG; Name: GW679769 (casopitant); Assigned to Arm(s): Arm 1
C: Arm Label: The study group (Gr. D); Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone, Drug: Ondansetron | Arm Label: the control group (Gr. N); Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Sodium Chloride Injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): The study group (Gr. D) | Intervention Type: DRUG; Name: 0.9% Sodium Chloride Injection; Assigned to Arm(s): the control group (Gr. N)
D: Arm Label: Ultrasound guided bilateral TAP block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transversus abdominis plane block (TAP BLOCK) | Arm Label: Instillation of surgical site with local anesthestic.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Instillation of surgical site with local anesthetic. | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Opioid IV medications (Control) | Intervention Type: PROCEDURE; Name: Transversus abdominis plane block (TAP BLOCK); Assigned to Arm(s): Ultrasound guided bilateral TAP block | Intervention Type: PROCEDURE; Name: Instillation of surgical site with local anesthetic.; Assigned to Arm(s): Instillation of surgical site with local anesthestic. | Intervention Type: PROCEDURE; Name: Opioid IV medications (Control); Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder
Brief Summary: The purpose of this study is to evaluate the long-term safety of methylphenidate HCL extended-release tablets at five dose levels in adults with Attention Deficit Hyperactivity Disorder (ADHD)


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate HCl (Concerta) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylphenidate HCl (Concerta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: OROS MPH, Drug: OROS MPH Tablets | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo Tablets | Intervention Type: DRUG; Name: OROS MPH; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: OROS MPH Tablets; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 002
C: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
D: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day.
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of methylphenidate HCl extended-release tablets at five dose levels compared to placebo in adults with Attention Deficit Hyperactivity Disorder (ADHD)


Options:
A: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate HCl (Concerta) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylphenidate HCl (Concerta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
D: Arm Label: Osmotic-Release Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Osmotic-Release Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Osmotic-Release Methylphenidate; Assigned to Arm(s): Osmotic-Release Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents
Brief Summary: The primary purpose of this study is to compare the compliance rates of adolescents who take oral contraceptives (OCPs) continuously to those who take OCPs cyclically.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Desogestrel-Ethinyl Estradiol 21 tablets | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desogestrel-Ethinyl Estradiol 28 tablets | Intervention Type: DRUG; Name: Desogestrel-Ethinyl Estradiol 21 tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desogestrel-Ethinyl Estradiol 28 tablets; Assigned to Arm(s): 2
B: Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo pill | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D
C: Arm Label: W82GO; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: W82GO | Arm Label: Smartphone; Type: EXPERIMENTAL; Interventions: Device: smartphone application | Intervention Type: BEHAVIORAL; Name: W82GO; Assigned to Arm(s): W82GO | Intervention Type: DEVICE; Name: smartphone application; Assigned to Arm(s): Smartphone
D: Arm Label: Mandometer; Type: EXPERIMENTAL; Interventions: Device: Mandometer, Behavioral: Lifestyle | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mandometer | Intervention Type: DEVICE; Name: Mandometer; Assigned to Arm(s): Control, Mandometer | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Mandometer

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy
Brief Summary: The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions.


Options:
A: Arm Label: ketamine up to 100 mcg/kg/min; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: midazolam & thiopental & propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): ketamine up to 100 mcg/kg/min, midazolam & thiopental & propofol
B: Intervention Type: DRUG; Name: intranasal lorazepam; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: intramuscular paraldehyde; Assigned to Arm(s): N/A
C: Arm Label: Intramuscular (IM) anticonvulsant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intramuscular route of active treatment | Arm Label: Intravenous (IV) anticonvulsant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous route of active treatment | Intervention Type: DRUG; Name: Intramuscular route of active treatment; Assigned to Arm(s): Intramuscular (IM) anticonvulsant | Intervention Type: DRUG; Name: Intravenous route of active treatment; Assigned to Arm(s): Intravenous (IV) anticonvulsant
D: Arm Label: Intranasal Midazolam 0.2mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Rectal Diazepam 0.3-0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diazepam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Intranasal Midazolam 0.2mg/kg | Intervention Type: DRUG; Name: Diazepam; Assigned to Arm(s): Rectal Diazepam 0.3-0.5 mg/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Brief Summary: This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer.


Options:
A: Arm Label: AGS-003 + Standard Treatment; Type: EXPERIMENTAL; Interventions: Biological: AGS-003 | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Treatment | Intervention Type: DRUG; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): AGS-003 + Standard Treatment
B: Arm Label: Arm A (sunitinib malate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sunitinib Malate | Arm Label: Arm B (sorafenib tosylate, placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Sorafenib Tosylate | Arm Label: Arm C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (sunitinib malate, placebo), Arm B (sorafenib tosylate, placebo), Arm C (placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm B (sorafenib tosylate, placebo) | Intervention Type: DRUG; Name: Sunitinib Malate; Assigned to Arm(s): Arm A (sunitinib malate, placebo)
C: Arm Label: SUNITINIB MALATE.; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib malate | Intervention Type: DRUG; Name: Sunitinib malate; Assigned to Arm(s): SUNITINIB MALATE.
D: Arm Label: Avelumab in combination with axitinib; Type: EXPERIMENTAL; Interventions: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736) | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Avelumab (MSB0010718C); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas
Brief Summary: Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine


Options:
A: Arm Label: A; Type: NO_INTERVENTION; Interventions: Genetic: cetuximab | Intervention Type: GENETIC; Name: cetuximab; Assigned to Arm(s): A
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine+erlotinib | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine+erlotinib+capecitabine | Intervention Type: DRUG; Name: Gemcitabine+erlotinib; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Gemcitabine+erlotinib+capecitabine; Assigned to Arm(s): Experimental
C: Arm Label: Erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Erlotinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: cetuximab + bevacizumab + gemcitabine; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Biological: bevacizumab, Drug: gemcitabine | Arm Label: cetuximab + bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Biological: bevacizumab | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): cetuximab + bevacizumab, cetuximab + bevacizumab + gemcitabine | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): cetuximab + bevacizumab, cetuximab + bevacizumab + gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): cetuximab + bevacizumab + gemcitabine | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): cetuximab + bevacizumab, cetuximab + bevacizumab + gemcitabine

Answer: D